How do you mitigate the risk of sticky or non-specific binders?

We prioritize clean leads from the start. Our protocol integrates stringent negative selection against non-transfected cells or irrelevant proteins. This allows us to filter out promiscuous clones before they reach the costly characterization stage, ensuring high specificity for your target.

Do you offer cross-species reactivity screening (e.g., Cyno/Mouse)?

Absolutely. To facilitate a smooth transition to toxicology and PK/PD studies, we integrate cross-panning strategies into our workflow. By alternating selection cycles between Human and Cynomolgus (or Mouse) targets, we identify high-affinity binders that recognize conserved epitopes across species, ensuring your leads are translational-ready.

Immunotherapy Discovery Services by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Developing the next breakthrough in immunotherapy requires more than just binding; it requires precise modulation of the immune system. Whether targeting novel checkpoints, co-stimulatory pathways, or tumor-associated antigens, Creative Biolabs combines massive premade human libraries (up to 10¹¹ diversity) with specialized functional screening. We fast-track the discovery of fully human agonists and antagonists that break tolerance, engage T-cells, and reshape the tumor microenvironment (TME).

Ready to Move Forward? Get a Quote

Antibody Discovery for Immunotherapy

The immuno-oncology (IO) landscape is shifting from simple blockade toward complex modulation and multi-specific engagement. Traditional immunization often struggles with conserved self-targets such as checkpoints and frequently fails to distinguish between agonistic and antagonistic epitopes. Creative Biolabs' Premade Human Antibody Library Service addresses these challenges by leveraging massive synthetic and naïve repertoires. We bypass natural tolerance mechanisms to identify rare, high-affinity binders against self-antigens. By employing functional screens that prioritize biological activity, we deliver safer, fully human candidates that are ready for clinical transition.

At Creative Biolabs, screening for immunotherapy candidates is a precision-engineered strategy. Our phage and yeast display platforms navigate the vast diversity of our premier human libraries with surgical accuracy. We utilize mechanism-driven panning, such as ligand competition to identify blockers or cell-based panning to maintain native conformations, to isolate clones with specific functional profiles. This rigorous process ensures that only the most robust immune modulators advance to development.

Fig.1 Antibody Discovery for Immunotherapy. (Creative Biolabs Authorized)

Premade Antibody Library based Antibody Discovery Service for CAR-T Therapy

Premade Antibody Library based Antibody Discovery Service for Immune Checkpoint

Premade Antibody Library based Antibody Discovery Service for ADC Therapy

Take the Next Step. Request Your Quote Today

How We Work

Inputs

Target, MoA goal (antagonist/blocker), species cross-reactivity (Human/Cyno), assay endpoints.

Workflow

Fig.2 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.3 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.4 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.5 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.6 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.7 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked functional binders, epitope bins, sequence families, IgG mini-panel, full report.

Discuss Your Screening Strategy with an Expert

Ready-to-Screen Antibody Libraries

Our libraries are the cornerstone of our discovery engine, built on robust, developability-optimized human frameworks.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Proven Excellence: Case Studies in Advanced Antibody Discovery

Leveraging our high-diversity Premade Synthetic V_HH & scFv Libraries, we provide specialized discovery solutions for the next generation of biotherapeutics. Our expertise spans from ultra-specific binders to functionally validated leads across diverse therapeutic modalities.

CAR-T Therapy: TCR-like V_HH for Neoantigens Immune Checkpoints: Potent Functional Blocking Leads ADC Development: Cross-Reactive Human scFv

Intracellular Target Discovery (pMHC Complexes)	Targeting neoantigens with single-amino-acid precision is the frontier of CAR-T safety. We specialize in isolating TCR-like V_HH antibodies that distinguish mutant peptides from wild-type counterparts with absolute specificity.
Capabilities	Multi-step in-solution competitive screening, MHC-framework depletion, and pMHC-specific enrichment.
Key Success	Zero cross-reactivity with wild-type peptides, ensuring high safety profiles for CAR-T candidates.

Read Full Service and Case Study

Your Perfect Solution Awaits. Request a Quote.

Related Services

Fig.14 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.15 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.16 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.17 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.18 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.19 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.19 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Fig.20 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Why Choose Us?

Massive 10¹¹ Diversity

Our fully human synthetic and semi-synthetic libraries ensure high-affinity candidates even against conserved self antigens and challenging checkpoints.

Low Immunogenicity by Design

We utilize validated fully human scaffolds to minimize Anti-Drug Antibody (ADA) risks which is a critical factor for chronic immunotherapy.

Precision Modulation

Proven expertise in isolating potent Antagonists (Checkpoint inhibitors) or Agonists (Co-stimulatory activators).

Cross-Species Reactivity

Tailored selection strategies ensure your leads are compatible with translational models (Cyno/Mouse) right out of the gate.

Weeks, Not Months

By bypassing animal immunization, our streamlined enrichment-to-IgG pipeline delivers functional leads in a fraction of the traditional timeline.

Radical Transparency & Data Ownership

You receive full NGS clustering data, functional datasets, and raw files. We provide modular project scopes with clear IP ownership to facilitate your path to the clinic.

Have Questions? Get a Quote Tailored to Your Needs

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

How do you mitigate the risk of sticky or non-specific binders?
We prioritize clean leads from the start. Our protocol integrates stringent negative selection against non-transfected cells or irrelevant proteins. This allows us to filter out promiscuous clones before they reach the costly characterization stage, ensuring high specificity for your target.
Do you offer cross-species reactivity screening (e.g., Cyno/Mouse)?
Absolutely. To facilitate a smooth transition to toxicology and PK/PD studies, we integrate cross-panning strategies into our workflow. By alternating selection cycles between Human and Cynomolgus (or Mouse) targets, we identify high-affinity binders that recognize conserved epitopes across species, ensuring your leads are translational-ready.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Ligand-Competitive Screening & Bioactivity Validation	For checkpoint inhibitors, binding is not enough, functional blocking is essential. We utilize Ligand-Mediated Competitive Elution to specifically recover clones that occupy the receptor-ligand interface.
Capabilities	Functional Interface targeting, dose-dependent blocking assays, and ligand-competitive selection.
Key Success	Rapid identification of clones with superior inhibitory potency compared to traditional non-blocking binders.

Species Cross-Reactivity & ADC Developability	To bridge the gap between discovery and clinical trials, we identify leads that recognize both Human and NHP (Non-Human Primate) orthologs, facilitating accurate PK/PD and toxicology assessments.
Capabilities	Parallel ortholog screening, high-throughput cross-reactivity profiling, and ADC-specific developability assessment (CDR liability mitigation).
Key Success	Optimized leads with balanced affinity across species and engineered sites for homogeneous conjugation.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: